farxiga

OVERVIEW

SGLT2 inhibitors
reduce reabsorption of glucose in the kidney

Dosing

• Available 5 mg and 10 mg tablets
• Oral
• Once daily in the morning

kinetics

• A: Tmax 2 hours, 78% bioavailablity
• D: 91% protein-bound
• M: Hepatic
• E: Renal 75%/Fecal 21%
• T1/2 12.9 hours

Store in a cool, dry place

safety

Adverse drug reactions:

• Hypotension, increased LDL cholesterol
• Impaired renal function
• Hypoglycemia with concomitant use of insulin
• Urinary tract infections, bladder cancer
• Hypersensitivity reactions

Drug interactions:

• Increased risk of low blood sugar and insulin
• Increased risk of low blood pressure and diuretics
• No drug-food interactions

Monitoring:

• HbA1c, blood glucose
• Renal function
• LDL cholesterol
• Volume status, blood pressure
• Signs of infection

special populations:

• Avoid in patients with an eGFR less than 60ml/min
• Contraindicated if eGFR is less than 30ml/min
• Elderly patients may be more sensitive
• Safety/efficacy not established in pediatrics
• Pregnancy category C/avoid during breastfeeding

fda information

Approved on
January 8, 2014

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 DM

indications:

• Monotherapy
• Initial therapy with metformin
• Add-on therapy to other glucose-lowering agents
• Potential off-label: weight loss

comparison

cliniCal trial

cost

$347 per month

cost comparison

COST COMPARISON

COST CONSIDERATIONS

• Delivery
• Storage
• Monitoring

sources

THANK YOU

Farxiga is dapagliflozin

SOURCES